摘要
目的:观察骨桥蛋白(OPN)和癌抗原125(CA125)联合检测在卵巢癌早期诊断中的价值。方法:采用酶联免疫吸附法(ELISA)测定32例卵巢癌患者(A组)及40例卵巢良性病变(B组)血清中ONP、CA125水平。结果:卵巢癌患者血清中OPN及CA125水平明显高于良性对照组(P<0.05);OPN、CA125检测的敏感性分别为81.3%和71.9%,OPN+CA125联合检测的敏感性为93.8%,均高于二者的单独检测;OPN、CA125检测的特异性分别为92.5%和87.5%,OPN+CA125联合检测的敏感性为95.0%,均高于二者的单项检测;OPN+CA125联合检测的阳性预测值和阴性预测值均高于二者的单项检测。结论:OPN联合CA125联合检测可提高卵巢癌的早期诊断水平。
Objective： To explore the early diagnostic value of combined detection of OPN and CA125 in ovarian cancer.Methods： The serum levels of OPN and CA125 were detected in 32 patients with ovarian cancer and 40 patients with benign ovarian tumor by ELISA method.Results： In comparison with benign ovarian tumor patients,the serum levels of OPN and CA125 in patients with ovarian cancer significantly increased（P0.05）.The sensitivities of OPN and CA125 were respectively 81.3% and 71.9%,the sensitivity of OPN combined with CA125 detection was 93.8%.The sensitivity of combined detection was higher than that by single detection of OPN or CA125.The specificity of OPN and CA125 were respectively 82.5% and 87.5%.The sensitivity of OPN combined with CA125 detection was 95.0%.The specificity of combined detection was higher than that by single detection of OPN or CA125.And the positive predictive value and negative predictive value was higher than that by single detection of OPN or CA125.Conclusion： Combined detection of OPN and CA125 could improve the early diagnosis of ovarian cancer.
出处
《现代生物医学进展》
CAS
2013年第4期691-693,共3页
Progress in Modern Biomedicine
